Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma

References

• Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004; 206: 149–157
   PubMed Web of Science ®Google Scholar
• Lindquist S. The heat-shock response. Annu Rev Biochem 1986; 55: 1151–1191
   PubMed Web of Science ®Google Scholar
• Xanthoudakis S, Nicholson D W. Heat-shock proteins as death determinants. Nat Cell Biol 2000; 2: E163–E165
   PubMedGoogle Scholar
• Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8: S55–S61
   PubMed Web of Science ®Google Scholar
• Munster P N, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001; 7: 2155–2158
   PubMed Web of Science ®Google Scholar
• Vasilevskaya I A, Rakitina T V, O'Dwyer P J. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res 2003; 63: 3241–3246
   PubMed Web of Science ®Google Scholar
• Yano M, Naito Z, Yokoyama M, Shiraki Y, Ishiwata T, Inokuchi M, et al. Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett 1999; 137: 45–51
   PubMed Web of Science ®Google Scholar
• Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor C W, Lykkesfeldt A E, Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 2003; 9: 4961–4971
   PubMed Web of Science ®Google Scholar
• Blagosklonny M V. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 2002; 16: 455–462
   PubMed Web of Science ®Google Scholar
• Hostein I, Robertson D, DiStefano F, Workman P, Clarke P A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001; 61: 4003–4009
   PubMed Web of Science ®Google Scholar
• Nielsen T O, Andrews H N, Cheang M, Kucab J E, Hsu F D, Ragaz J, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004; 64: 286–291
   PubMed Web of Science ®Google Scholar
• Solit D B, Basso A D, Olshen A B, Scher H I, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003; 63: 2139–2144
   PubMed Web of Science ®Google Scholar
• Amin H M, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 2001; 115: 287–297
   PubMed Web of Science ®Google Scholar
• Pene F, Claessens Y E, Muller O, Viguie F, Mayeux P, Dreyfus F, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002; 21: 6587–6597
   PubMed Web of Science ®Google Scholar
• Mesa R A, Loegering D, Powell H L, Flatten K, Arlander S J, Dai N T, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005; 106: 318–327
   PubMed Web of Science ®Google Scholar
• Pockley A G, Bulmer J, Hanks B M, Wright B H. Identification of human heat shock protein 60 (Hsp60) and anti-Hsp60 antibodies in the peripheral circulation of normal individuals. Cell Stress Chaperones 1999; 4: 29–35
   PubMed Web of Science ®Google Scholar
• Richter K, Buchner J. Hsp90: chaperoning signal transduction. J Cell Physiol 2001; 188: 281–290
   PubMed Web of Science ®Google Scholar
• Lai B T, Chin N W, Stanek A E, Keh W, Lanks K W. Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol 1984; 4: 2802–2810
   PubMed Web of Science ®Google Scholar
• Supko J G, Hickman R L, Grever M R, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995; 36: 305–315
   PubMed Web of Science ®Google Scholar
• Schulte T W, Neckers L M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42: 273–279
   PubMed Web of Science ®Google Scholar
• Schulte T W, Blagosklonny M V, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995; 270: 24585–24588
   PubMed Web of Science ®Google Scholar
• Goetz M P, Toft D O, Ames M M, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003; 14: 1169–1176
   PubMed Web of Science ®Google Scholar
• Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23: 4152–4161
   PubMed Web of Science ®Google Scholar
• Isaacs J S, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003; 3: 213–217
   PubMed Web of Science ®Google Scholar
• Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002; 2: 3–24
   PubMed Web of Science ®Google Scholar
• Banerji U, Clarke M, Walton M, O'Donnell A, Raynaud F, Turner A. Preclinical and clinical activity of the molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in malignant melanoma. Proc Am Assoc Cancer Res 2003; 44: 587
   Google Scholar
• Nguyen D M, Lorang D, Chen G A, Stewart J Ht, Tabibi E, Schrump D S. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 2001; 72: 371–378
   PubMed Web of Science ®Google Scholar
• Takimoto C H, Diggikar S. Heat shock protein and proteasome targeting agents. Hematol Oncol Clin North Am 2002; 16: 1269–1285
   PubMed Web of Science ®Google Scholar
• Hideshima T, Anderson K C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927–937
   PubMed Web of Science ®Google Scholar
• Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm M F, Fritz L C, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407–410
   PubMed Web of Science ®Google Scholar
• Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res 2002; 62: 1559–1566
   PubMed Web of Science ®Google Scholar
• Goes F S, Martin J. Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1. Eur J Biochem 2001; 268: 2281–2289
   PubMedGoogle Scholar
• de Carcer G, do Carmo Avides M, Lallena M J, Glover D M, Gonzalez C. Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability. Embo J 2001; 20: 2878–2884
   PubMed Web of Science ®Google Scholar
• Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio P C, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003; 100: 13791–1376
   PubMed Web of Science ®Google Scholar
• Denis M, Gustafsson J A. The Mr approximately 90,000 heat shock protein: an important modulator of ligand and DNA-binding properties of the glucocorticoid receptor. Cancer Res 1989; 49: 2275S–2281S
   PubMed Web of Science ®Google Scholar
• Alkan S, Izban K F. Immunohistochemical localization of phosphorylated AKT in multiple myeloma. Blood 2002; 99: 2278–2279
   PubMed Web of Science ®Google Scholar
• Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, Neckers L, et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem 2000; 275: 10519–10526
   PubMed Web of Science ®Google Scholar
• Rakitina T V, Vasilevskaya I A, O'Dwyer P J. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygel danamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res 2003; 63: 8600–8605
   PubMed Web of Science ®Google Scholar
• Ni H, Ergin M, Huang Q, Qin J Z, Amin H M, Martinez R L, et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 2001; 115: 279–286
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang H G, Bhalla K N. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood 2003; 102: 269–275
   PubMed Web of Science ®Google Scholar
• Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, et al. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003; 63: 6174–6177
   PubMed Web of Science ®Google Scholar
• Chauhan D, Auclair D, Robinson E K, Hideshima T, Li G, Podar K, et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002; 21: 1346–1358
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374–14379
   PubMed Web of Science ®Google Scholar